Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Phone520-365-3100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.67 million
Profitability
Miscellaneous
Employees287
Next Earnings Date8/5/2019 (Estimated)
OptionableOptionable
Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions
What is Accelerate Diagnostics' stock symbol?
Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."
How were Accelerate Diagnostics' earnings last quarter?
Accelerate Diagnostics Inc (NASDAQ:AXDX) posted its quarterly earnings results on Thursday, May, 9th. The medical research company reported ($0.40) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.03. The medical research company had revenue of $1.75 million for the quarter, compared to the consensus estimate of $2.12 million. Accelerate Diagnostics had a negative return on equity of 130.94% and a negative net margin of 1,352.80%. View Accelerate Diagnostics' Earnings History.
When is Accelerate Diagnostics' next earnings date?
What price target have analysts set for AXDX?
4 Wall Street analysts have issued 12 month price targets for Accelerate Diagnostics' shares. Their forecasts range from $16.00 to $25.00. On average, they anticipate Accelerate Diagnostics' share price to reach $21.00 in the next twelve months. This suggests a possible upside of 8.8% from the stock's current price. View Analyst Price Targets for Accelerate Diagnostics.
What is the consensus analysts' recommendation for Accelerate Diagnostics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Accelerate Diagnostics.
What are Wall Street analysts saying about Accelerate Diagnostics stock?
Here are some recent quotes from research analysts about Accelerate Diagnostics stock:
- 1. According to Zacks Investment Research, "Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, a rapid diagnostic platform for diagnosis in life-threatening bacterial infections and OptiChem(R) surface coatings for use in micro arraying components. Accelerate Diagnostics Inc., formerly known as Accelr8 Technology Corp., is based in Denver, Colorado. " (5/14/2019)
- 2. BTIG Research analysts commented, "Neutral AXDX reported Q1 revenue of $1.75M, short of consensus’ $1.9M forecast. Revenue was down sequentially by 4%. Although we had expected a revenue stepdown given the typical cadence of placements-to- conversions, the magnitude of the decline was less than we expected. In Q1, the company added 75 commercially contracted placements vs. 133 in 4Q18; to clarify, commercial placements refer to customers that have agreed to install and run tests (may or may not be active users). The company still sees a 4-9 month lag before instruments become active. On expectations for 2019, mgmt continues to target 300-400 placements as a full transition to the rental model and more comprehensive body of positive studies may drive up volumes." (5/12/2019)
Has Accelerate Diagnostics been receiving favorable news coverage?
Press coverage about AXDX stock has trended positive recently, InfoTrie reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Accelerate Diagnostics earned a news impact score of 2.3 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 9.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future.
Who are some of Accelerate Diagnostics' key competitors?
Some companies that are related to Accelerate Diagnostics include Coherent (COHR), Horiba (HRIBF), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Quanterix (QTRX), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), Arrayit (ARYC), Precipio (PRPO), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Scientific Industries (SCND), Pressure Biosciences (PBIO) and PositiveID (PSID).
What other stocks do shareholders of Accelerate Diagnostics own?
Who are Accelerate Diagnostics' key executives?
Accelerate Diagnostics' management team includes the folowing people:
- Mr. Lawrence Mehren, Pres, CEO, Director and Interim Head of Europe, Middle East & Africa (Age 53)
- Mr. Steve Reichling, Chief Financial Officer (Age 41)
- Mr. Ron Price, Sr. VP & Head of Commercial Operations - Americas (Age 55)
- Mr. Kurt Reinhardt, Head of Operations
- Dr. Romney M. Humphries, Chief Scientific Officer (Age 38)
Who are Accelerate Diagnostics' major shareholders?
Accelerate Diagnostics' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.08%), ArrowMark Colorado Holdings LLC (2.04%), FMR LLC (1.57%), Blair William & Co. IL (1.23%), Amundi Pioneer Asset Management Inc. (0.94%) and Chicago Capital LLC (0.88%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, John Patience, Lawrence Mehren, Steven Reichling and Thomas D Brown. View Institutional Ownership Trends for Accelerate Diagnostics.
Which major investors are selling Accelerate Diagnostics stock?
AXDX stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Trellus Management Company LLC, BlackRock Inc., Goldman Sachs Group Inc., JPMorgan Chase & Co., Thompson Investment Management Inc., CIBC Private Wealth Group LLC and California State Teachers Retirement System. View Insider Buying and Selling for Accelerate Diagnostics.
Which major investors are buying Accelerate Diagnostics stock?
AXDX stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Cadian Capital Management LP, ArrowMark Colorado Holdings LLC, FMR LLC, Chicago Capital LLC, Blair William & Co. IL, Griffin Asset Management Inc. and Geode Capital Management LLC. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, John Patience, Steven Reichling and Thomas D Brown. View Insider Buying and Selling for Accelerate Diagnostics.
How do I buy shares of Accelerate Diagnostics?
Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Accelerate Diagnostics' stock price today?
One share of AXDX stock can currently be purchased for approximately $19.30.
How big of a company is Accelerate Diagnostics?
Accelerate Diagnostics has a market capitalization of $1.05 billion and generates $5.67 million in revenue each year. The medical research company earns $-88,330,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Accelerate Diagnostics employs 287 workers across the globe.
What is Accelerate Diagnostics' official website?
How can I contact Accelerate Diagnostics?
Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]
MarketBeat Community Rating for Accelerate Diagnostics (NASDAQ AXDX)
MarketBeat's community ratings are surveys of what our community members think about Accelerate Diagnostics and other stocks. Vote "Outperform" if you believe AXDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
